Studying New Ways to Target Adult T-Cell Leukemia and Lymphoma Cells
Studies cell samples from adults with resistant T-cell leukemia or lymphoma, testing drug combinations.
Plain-language title generated from the registry record
Registry title: Novel Therapeutic Approach for Human T-cell Malignancies
Key facts
- Where
- Naples and Padova, ItalySee the 2 sites
Where in Italy
- Istituto Nazionale Tumori Fondazione G. PascaleNaples, ItalyTaking people
- Istituto Oncologico VenetoPadova, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Istituto Oncologico Veneto IRCCS
- Trial code
- NCT06600568
- Record updated
- 6 August 2026
- Original description
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.Read full original descriptionShow less
Identification of Targetable Vulnerabilities in Redox Homeostasis Pathways as a Novel Therapeutic Approach for Human T-cell Malignancies
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined.
The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.
Inclusion: Patients with pre- and post-thymic T-cell leukemia/lymphoma; Patients of both sexes; Age of patients older than 18 years; Patient is willing to provide written and signed informed consent for participation in the study.
Exclusion: -Serious illness or medical condition that does not allow the patient to be managed according to standard treatment protocols, including uncontrolled active infection.